2018, Number 3
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2018; 56 (3)
Adequate restitution in primary hypothyroidism depending on levothyroxine formulations
Tamez-Pérez HE, García-de la Cruz G, Garza-Garza LA, Tamez-Peña AL, Hernández-Coria MI, Soni-Duque D
Language: Spanish
References: 24
Page: 255-260
PDF size: 838.32 Kb.
ABSTRACT
Background: The prevalence of primary hypothyroidism
(PH) is around 3.8%-4.6% in general population. Out of
patients under treatment with levothyroxine, approximately
40% show altered levels of thyroid-stimulating hormone
(TSH).
Objective: To determine the prevalence of euthyroid sick
syndrome in patients under treatment for PH in two local
clinics, considering that the number of formulations of
levothyroxine could be a contributing factor to the inadequate
restitution.
Methods: Descriptive, comparative cohort conducted with PH
patients who were treated with a stable dose of levothyroxine
for at least six months. Patients treated with mixtures of
liothyronine/levothyroxine, with postsurgical hypothyroidism,
pregnant, breastfeeding or mentally ill were discarded.
Medical clinic 1 was a public center that had only access to
levothyroxine of 100 µg, and medical clinic 2 was a private
clinic with access to 25, 50, 75 and 100 µg levothyroxine
formulations.
Results: A total of 350 patients were evaluated. 190 patients
were obtained at clinic 1, and 160 patients at clinic 2. At clinic
1, only 63% received the appropriate dose, while at clinic 2,
75% were medicated with the correct dose (
p = 0.033).
Conclusion: In the public center, 39% of patients did not
receive appropriate dose of levothyroxine; however, in the
private clinic, which had more drug formulations, the
percentage of patients lowered to 25%. Therefore, the
number of formulations could be a factor for the risk of
inadequate restitution.
REFERENCES
Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Andrada NC, Bravo PP, et al; Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS). Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metab. 2013; Jun;57(4):265-91.
Chakera AJ, Pearce SHS, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Des Devel Ther. 2012 Jan;6:1-11.
De Santillana SP, Medrano Ortiz-de Zárate ME. Guía de Práctica Clínica Diagnóstico y Tratamiento de Evidencias y Recomendaciones. México: Secretaría de Salud; 2009.
Okosieme OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of thyroid hormone replacement in a general population. QJM. 2011;104(5):395-401.
Mithal A, Dharmalingam M, Tewari N. Are patients with primary hypothyroidism in India receiving appropriate thyroxine replacement? An observational study. Indian J Endocrinol Metab. 2014;18(1):83-8.
Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients. Res Cardiovasc Med. 2015;4(4):e29094.
Sun X, Sun Y, Li WC, Chen CY, Chiu YH, Chien HY, et al. Association of Thyroid-stimulating Hormone and Cardiovascular Risk Factors. Intern Med. 2015;54(20):2537-44.
Comisión Interinstitucional del Cuadro Básico y Catálogo de Insumos del Sector Salud. Cuadro básico y catálogo de medicamentos. México: Consejo de Salubridad General; 2014. Disponible en http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadrobasico/ med/catalogo/2014/EDICION_2014_MEDICAMENT OS.pdf
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid 2 Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-751.
Zacarías AR, Magaña EG, Meguro EN. Manejo del hipotiroidismo congénito con dosis diarias no equitativas de levotiroxina. Revista de Endocrinología y Nutrición. 2009;17(2):66-70.
Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Subclinical Thyroid Dysfunction and Fracture Risk. JAMA. 2015 May 26;313(20):2055-65.
Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(May):186-93.
Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract. 1993;43(368):107-9.
Devdhar M, Drooger R, Pehlivanova M, Singh G, Jonklaas J. Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid. 2011;21(8):821-7.
Vigário PDS, Vaisman F, Coeli CM, Ward L, Graf H, Carvalho G, et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor healthrelated quality of life-a Brazilian multicentre study. Endocrine. 2013;44(2):434-40.
Robertson HM, Narayanaswamy AK, Pereira O, Copland SA, Herriot R, McKinlay AW, et al. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid. 2014;24(12):1765-71.
Morris JC. How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement? Clin Endocrinol (Oxf). 2009;70(5):671-3.
World Health Organization. WHO Model list of essential medicines. 19° Edition. April 2015. Disponible en http://www.who.int/medicines/publications/essentialmedicin es/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
World Health Organization. WHO Model List of Essential Medicines for Children. 19° Edition. April 2015. Disponible en http://www.who.int/medicines/publications/essentialmedicin es/EMLc_2015_FINAL_amended_AUG2015.pdf?ua=1
Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-7.
Food and Drug Administration (FDA). Tablet Splitting: A Risky Practice. 2009.
Tamez-Pérez HE, Martínez E, Quintanilla-Flores DL, Tamez-Peña AL, Gutiérrez-Hermosillo H, Díaz de León- González E. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study. Med Clin (Barc). 2012;138(11):475-7. 4
Han C, He X, Xia X, Li Y, Shi X, Shan Z, et al. Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(8):e0135233.
Palma CC, Pavesi M, Nogueira VG, Clemente EL, Vasconcellos Mde F, Pereira LC Júnior, et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol Metab Syndr. 2013;5(1):58.
Full text